Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone mass ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.

LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.

Amgen Inc. (AMGN) received a major boost recently with the company gaining US Food and Drug Administration (FDA) approval for Xgeva (denosumab) for the prevention of skeletal-related events (SREs) in ...